Sodium glycerophosphate

Overview

Sodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels . Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body . The extent of this reaction is dependent on the activity of serum alkaline phosphatases.

Indication

Sodium glycerophosphate is indicated for use as a source of phosphate in total parenteral nutrition . It is used in combination with amino acids, dextrose, lipid emulsions, and other electrolytes.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E	2025/02/24	NCT06842134	Phase 1	Completed	Baxter Healthcare Corporation
A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)	2025/02/24	NCT06842121	Phase 1	Completed	Baxter Healthcare Corporation
The Efficacy and Safety of Diluted Oral Phosphate Enema Versus Intravenous Sodium Glycerophosphate in The Treatment of Hypophosphatemia in ICU Patients	2024/10/22	NCT06651892	Phase 2	Completed	Ain Shams University
Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU	2020/08/20	NCT04519762	Phase 4	UNKNOWN	Ain Shams University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Glycophos	Fresenius Kabi USA, LLC	63323-241	INTRAVENOUS	216 mg in 1 mL	1/16/2019
Kabiven	Fresenius Kabi USA, LLC	63323-712	INTRAVENOUS	147 mg in 100 mL	8/2/2023
Perikabiven	Fresenius Kabi USA, LLC	63323-714	INTRAVENOUS	105 mg in 100 mL	8/7/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
GLYCOPHOS CONCENTRATE FOR SOLUTION FOR INFUSION 216 mg/ml	FRESENIUS KABI NORGE AS	SIN11858P	INJECTION	216 mg/ml	4/1/2002
SmofKabiven Emulsion for Infusion	Fresenius Kabi AB, Fresenius Kabi Austria GmbH	SIN14286P	INJECTION, EMULSION	4.18g /1000ml	1/8/2013
KABIVEN PERIPHERAL EMULSION FOR INFUSION	FRESENIUS KABI AB, FRESENIUS KABI AUSTRIA GMBH	SIN11718P	INJECTION	1.0 g/l	11/16/2001
OLICLINOMEL N7-1000 E EMULSION FOR INFUSION	BAXTER SA, Ajinomoto North America Incorporated (Intermediate)	SIN12539P	EMULSION	2.14 g/l	5/6/2004
PERIOLIMEL N4E Emulsion for Infusion	Ajinomoto Health & Nutrition North America Inc. (Intermediate), Baxter S.A	SIN16888P	EMULSION	1.91g/L	10/20/2023
SmofKabiven Peripheral Emulsion for Infusion	Fresenius Kabi AB	SIN14287P	INJECTION, EMULSION	4.18g /1000ml	1/8/2013
OLICLINOMEL N4-550 E EMULSION FOR INFUSION	BAXTER SA, Ajinomoto North America Incorporated (Intermediate)	SIN12542P	EMULSION	2.14 g/l	5/6/2004
KABIVEN EMULSION FOR INFUSION	FRESENIUS KABI AB, FRESENIUS KABI AUSTRIA GMBH	SIN11657P	INJECTION	1.5 g/1000 ml	9/4/2001
OLIMEL N9E Emulsion for Infusion	Ajinomoto Health & Nutrition North America Inc. (Intermediate), Baxter S.A	SIN16890P	EMULSION	3.67g/L	10/20/2023
SMOFKABIVEN EXTRA NITROGEN EMULSION FOR INFUSION	Fresenius Kabi AB, Site Uppsala	SIN16135P	INJECTION, EMULSION	2.3g/1000ml	3/24/2021

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
Sodium Glycerophosphate Injection	开封制药（集团）有限公司	国药准字H20073929	化学药品	注射剂	1/5/2022
Sodium Glycerophosphate Injection	北京布霖生物科技有限公司	国药准字H20253285	化学药品	注射剂	1/24/2025
Sodium Glycerophosphate Injection	湖南科伦制药有限公司	国药准字H20059292	化学药品	注射剂	12/11/2020
Sodium Glycerophosphate Injection	华夏生生药业（北京）有限公司	国药准字H20253284	化学药品	注射剂	1/24/2025
Sodium Glycerophosphate Injection	无锡凯夫制药有限公司	国药准字H20058518	化学药品	注射剂	7/28/2020
Sodium Glycerophosphate Injection	成都百裕制药股份有限公司	国药准字H20084578	化学药品	注射剂	3/9/2023
Sodium Glycerophosphate Injection	山东新华制药股份有限公司	国药准字H20058605	化学药品	注射剂	10/17/2023
Sodium Glycerophosphate Injection	费森尤斯卡比华瑞制药有限公司	国药准字H10950042	化学药品	注射剂	5/19/2020

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
OLIMEL N9E EMULSION FOR INFUSION	N/A	Baxter Healthcare Ltd	N/A	N/A	10/24/2013

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1970 mL	180546	Fresenius Kabi Australia Pty Ltd	Medicine	A	1/9/2012
OLICLINOMEL N4-550 E 1000 mL IV emulsion for infusion with electrolytes bag	136599	Baxter Healthcare Pty Ltd	Medicine	A	9/4/2007
OLICLINOMEL N4-550 E 2500 mL IV emulsion for infusion with electrolytes bag	141396	Baxter Healthcare Pty Ltd	Medicine	A	9/4/2007
OLIMEL N5-860E Emulsion for intravenous infusion	197417	Baxter Healthcare Pty Ltd	Medicine	A	8/9/2013
SMOFKABIVEN LOW OSMO amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 2500 mL biofine bag	329619	Fresenius Kabi Australia Pty Ltd	Medicine	A	8/27/2020
OLIMEL N7-960E Emulsion for intravenous infusion	197418	Baxter Healthcare Pty Ltd	Medicine	A	8/9/2013
SMOFKABIVEN LOW OSMO amino acids 2.5%, electrolytes 0.4%, lipids 3.5% & glucose 6.8% emulsion for intravenous infusion 1400 mL biofine bag	329617	Fresenius Kabi Australia Pty Ltd	Medicine	A	8/27/2020
OLICLINOMEL N5-800 E 2000 mL IV emulsion for infusion with electrolytes bag	141383	Baxter Healthcare Pty Ltd	Medicine	A	9/4/2007
SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 2463 mL	180547	Fresenius Kabi Australia Pty Ltd	Medicine	A	1/9/2012
SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 1477 mL	180543	Fresenius Kabi Australia Pty Ltd	Medicine	A	1/9/2012

AI-Powered Research

Premium Access